The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00.

About Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterised by a decline in memory, thinking, behaviour and the ability to perform everyday activities.

It is estimated that 9.7 million people in Europe alone already live with Alzheimer’s disease and dementia. With a rapidly ageing population, it is a growing public health concern worldwide as this number is projected to rise to a staggering 14 million by 2030.

RETHINKING Alzheimer’s disease: Detection and diagnosis

The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper RETHINKING Alzheimer’s disease: Detection and diagnosis. This paper is the first of EBC’s “RETHINKING Alzheimer’s disease” project, looking at how to improve the detection, diagnosis, care and monitoring of AD.

The White Paper is particularly looking at how to detect and diagnose the disease at an earlier stage (at mild cognitive impairment – MCI  – stage) and what new care pathways would need to be implemented to reach out to patients at that stage. With disease modifying treatments targeting patients with MCI potentially coming to market in the near future, it is also important to see how prepared healthcare systems are to provide these new treatments.  

Read more about the RETHINKING Alzheimer’s disease project

You can look forward to a keynote speech on the value of an early diagnosis, a panel discussion featuring experts involved in the RETHINKING Alzheimer’s disease project, a policy panel with key stakeholders at the European Parliament and the European Commission and much more. Follow the EBC social media channels (TwitterLinkedIn) and dedicated newsletter for all the latest updates – more information coming soon!

Add to Calendar